Trump’s 100% Drug Tariff Could Gut U.S. Buyers, Not Big Pharma
-
最新报道：Trump's proposed 100% tariff on imported drugs would double costs for branded medications, with economists warning American patients and insurers will bear the full burden rather than foreign pharmaceutical companies. Economist Justin Wolfers notes patented drugs face no competition and inelastic demand, creating textbook conditions where U.S. buyers absorb price increases. Pharmaceutical ETFs show mixed performance as investors assess the impact, while patients with chronic conditions face impossible choices between medications and essential expenses.
下一篇
FTX Payouts, U.S. Tariffs, Nonfarm Payrolls: Crypto Week Ahead
- FTX creditors begin receiving $1.6 billion in the third payout tranche under its bankruptc...
24小时热点
热点专题
407042